导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 6.61% | 973/4773 |
| 近一周 | -2.72% | 2932/5462 |
| 近一月 | -8.50% | 4271/5421 |
| 近一季 | -1.38% | 986/5209 |
| 近半年 | 4.94% | 800/4920 |
| 近一年 | 6.48% | 1456/4366 |
| 近两年 | 91.19% | 677/2954 |
| 近三年 | 57.96% | 470/2253 |
| 成立以来 | 35.94% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.45% 3840/4961 |
22.45% 1127/5312 |
- - |
- - |
| 2025 | 33.61% 1105/4813 |
4.08% 996/3635 |
0.30% 2711/4076 |
38.76% 840/4524 |
-7.76% 3838/4813 |
| 2024 | 13.45% 1138/3463 |
-3.82% 1566/2808 |
-5.08% 1637/3014 |
17.15% 1261/3129 |
6.07% 552/3463 |
| 2023 | 1.88% 342/2656 |
23.16% 117/2280 |
-4.08% 1037/2385 |
-11.31% 2050/2515 |
-2.76% 527/2655 |
| 2022 | -30.54% 1635/2207 |
-21.51% 1631/1919 |
1.29% 1489/2016 |
-16.27% 1433/2113 |
4.35% 557/2208 |
| 2021 | 8.97% 465/1822 |
-6.43% 1001/1255 |
11.62% 366/1330 |
-3.36% 634/1466 |
7.96% 170/1822 |
| 2020 | - - |
- - |
24.04% 179/1067 |
1.93% 1017/1164 |
5.72% 776/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证科技50策略ETF联接C VS. 长安沪深300非周期A(740101) |